

Rosalie Liccardo Pacula, Ph.D.

Senior Economist ■ RAND Corporation ■ 1776 Main St. ■ Santa Monica CA 90407-2138 ■
(310) 393-0411 ext 6494 ■ Internet: pacula@rand.org

EDUCATION

- Ph.D. Economics, Duke University, September 1995.
Thesis Title: The Development of Demand for Intoxicating Substances by Adolescents
- M.A. Economics, Duke University, 1992.
- B.S. Political Science and Economics, Santa Clara University, 1990.

PROFESSIONAL EXPERIENCE

- 2013 – Present Director, BING Center for Health Economics, RAND Corporation
- 2012 - 2013 Acting Director, Economics, Finance and Organization Unit, RAND Health
- 2007 - Present Professor, Pardee RAND Graduate School of Public Policy
- 2005 – Present Co-Director, Drug Policy Research Center, RAND
- 2005 – Present Senior Economist, RAND
- 1997 – Present Faculty Research Fellow, National Bureau of Economic Research
- 2002 – 2004 Economist, RAND
- 1998 – 2001 Associate Economist, RAND
- 1997 – 1998 Visiting Senior Research Analyst, Health Research and Policy Centers, University of Illinois at Chicago
- 1995 – 1998 Assistant Professor of Economics, School of Business Administration, University of San Diego

RESEARCH INTERESTS

Health Promotion and Health Care, Drug Markets, Drug Policy, Health Policy, Health Insurance, Behavioral Health Care and Delivery of Services, Substance Abuse, and Economics and Crime.

PUBLICATIONS

Journal Articles

Powell D, **Pacula RL**, and M Jacobson (2018). “Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers?” *Journal of Health Economics*. 25: 29-42.

Azofeifa A, Sherman LJ, Mattson ME, and **RL Pacula** (2018). “Marijuana buyers in the United States, 2010-2014” *Drug and Alcohol Dependence*, 183, 34-42.

Pacula RL and D Powell (2018). “A Supply Side Perspective on the Opioid Crisis” *Journal of Policy Analysis and Management*. Early view: [at wileyonlinelibrary.com/journal/pam](http://at.wileyonlinelibrary.com/journal/pam).
DOI:10.1002/pam.22049

Alpert A, Powell D and **RL Pacula** (Forthcoming) “Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids” *American Economic Journal: Economic Policy*.

Sarvet AL, Wall MM, Fink DS, Greene E, Le A, Boustead AE, **Pacula RL**, Keyes KM, Cerda M, Galea S and DS Hasin (Forthcoming). "Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis" *Addiction*.

- Cerdá M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, O'Malley PM, **Pacula RL**, Galea S, and DS Hasin (2017). "State Recreational Marijuana Laws and Adolescent Marijuana Use" *JAMA Pediatrics*, 171(2): 142-149.
- Nicosia N, MacDonald J and **RL Pacula**. (2017). "Does Mandatory Diversion to Drug Treatment Eliminate Racial Disparities in the Incarceration of Drug Offenders? An Examination of California's Prop 36" *Journal of Quantitative Criminology*, 33(1): 179-205.
- Klieger, SB, Allen L, **Pacula RL**, Ibrahim JK and S Burris (2017). "Mapping medical marijuana: State laws regulating patients, product safety and dispensaries, 2016." *Addiction*. 112, 2206-2216.
- Breslau J, Yu H, Han B, **Pacula RL**, Burns R and B Stein (2017). "Did the Dependent Coverage Expansion Increase Risky Substance Use Among Young Adults." *Drug and Alcohol Dependence*, 178, 556-561.
- Hunt P and **RL Pacula** (2017). "Early Impacts of Marijuana Legalization? An Evaluation of Prices in Colorado and Washington." *Journal of Primary Prevention*, 38(3): 221-248. DOI: 10.1007/s10935-017-0471-x.
- Pacula RL** and R Smart (2017). "Effects of Changes in Marijuana Laws on Marijuana Use and Disorders: Medical Marijuana and Marijuana Legalization," *Annual Review of Clinical Psychology*, 13(1): 397-419.
- Kilmer, B and **RL Pacula** (2017). Building the data infrastructure to evaluate cannabis legalization. *Addiction*, 112(7): 1140-1141.
- Stevens, A and **RL Pacula** (2017). Advancing knowledge on cannabis policy using evidence from North America. *International Journal of Drug Policy*, 42: 36-38.
- Kilmer, B and **RL Pacula** (2017). "Understanding and learning from the diversification of cannabis supply laws." *Addiction*, 112(7): 1128-1135.
- Stein BD, Mendelsohn J, Gordon AJ, Dick AW, Burns RM, Sorbero M, and **RL Pacula** (2017). "Opioid Analgesic and Benzodiazepine Prescribing Among Medicaid-enrollees with Opioid Use Disorders: The Influence of Provider Communities" *Journal of Addictive Diseases*, 36(1): 14-22.
- Stein BD, Sorbero M, Dick AW, **Pacula RL**, Burns RM and AJ Gordon (2016). "Underutilized physician capacity to treat opioid use disorder with buprenorphine opioid agonist medication assisted treatment" *JAMA*, 316(11): 1211-1212.
- Pacula RL**, Jacobson MJ, and E Maksabedian. (2016). "In the Weeds: A Baseline View of Marijuana Use Among Legalizing States and Their Neighbors." *Addiction*, 111(6): 973-980. doi: [10.1111/add.13282](https://doi.org/10.1111/add.13282).
- Blanchard J, Hunter S, Osilla KC, Stewart W, Walters J and **RL Pacula** (2016). "A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse." *Military Medicine*, 181(5): 410-423.
- Burns RM, **Pacula RL**, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, and BD Stein (2016). "Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013." *Substance Abuse*, 37(1): 63-69.
- Stein BD, Dick AW, **Pacula RL**, Gordon AJ, Burns RM, Leslie DL and M Sorbero (2015). "Where is Buprenorphine Dispensed for Treating Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties." *Milbank Quarterly*, 93(3): 561-583.

- Hasin DS, Wall M, Keyes KM, Cerda M, Schulenberg J, O'Malley P, Galea S, **Pacula RL**, and T Feng (2015). "State Medical Marijuana Laws and Adolescent Marijuana Use in the United States: 1991-2012." *The Lancet-Psychiatry*, 2(7): 601-608.
- Olmstead TA, Alessi SM, Kline B, **Pacula RL** and NM Petry (2015). "The Price Elasticity of Demand for Heroin: Matched Longitudinal and Experimental Evidence." *Journal of Health Economics*, 41, 59-71.
- Pacula RL**, Powell D, Heaton P and E Sevigny (2015). "Assessing the Effects of Medical Marijuana Laws on Marijuana: The Devil is in the Details." *Journal of Public Policy Analysis and Management*, 34(1): 7-31.
- Dick AW, **Pacula RL**, Gordon AJ, Sorbero M, Burns RM, Farmer CM, Leslie DL, and BD Stein (2015). "Increasing Access to Opioid Agonist Treatment in U.S. Treatment Shortage Areas." *Health Affairs*, 34(6), 1028-1034.
- Taylor E, Saltzman E, Bauhoff S, **Pacula RL** and C Eibner (2015). "More Choice on the Exchanges May Reduce the Value of the Subsidies for Low-Income Enrollees" *Health Affairs*, 34(1): 104-110.
- Stein BD, Gordon AJ, Dick AW, Burns RM, **Pacula RL**, Farmer CM, Leslie DL and M Sorbero (2015). "Supply of Buprenorphine Waivered Physicians: The influence of state policies." *Journal of Substance Abuse Treatment*, 48(1): 104-111.
- Stein BD, Gordon AJ, Dick A, Burns RM, **Pacula RL**, Farmer C, Leslie D. (2015). "Physician Supply for the Treatment of Opioid Use Disorders: The influence of state policies." *Drug and Alcohol Dependence*, 146, e107-e108.
- Pacula, RL**, Gordon AJ, Dick AW, Burns RB, Farmer C, Leslie D, Sorbero M, and BD Stein (2015). "Expansion of buprenorphine opioid agonist therapy in the United States: Facility-level factors." *Drug & Alcohol Dependence*, 146, e179.
- Pacula RL** and EL Sevigny (2014). "Marijuana Liberalizations Policies: Why We Can't Learn Much from Policy Still in Motion." *Journal of Policy Analysis and Management*, 33(1): 212-221.
- Pacula RL** and EL Sevigny (2014). "Natural experiments in a complex and dynamic environment: The need for a measured assessment of the evidence." *Journal of Policy Analysis and Management*, 33(1): 232-235.
- MacDonald J, Arkes J, Nicosia N, and **RL Pacula**. (2014). "Decomposing Racial Disparities in Prison and Drug Treatment: Commitments for Criminal Offenders in California." *Journal of Legal Studies*, 43(1): 155-187.
- Pacula RL**, Kilmer B, Wagenaar A, Chaloupka FJ, and JP Caulkins (2014). "Developing Public Health Regulations for Marijuana: Lessons from Alcohol and Tobacco." *American Journal of Public Health*, 104(6), 1021-1028.
- Sevigny E, **Pacula RL**, and P Heaton (2014). "The effects of medical marijuana laws on potency." *International Journal of Drug Policy*, 25(2): 308-319.
- Pacula RL** and R Lundberg (2014). "Why Changes in Price Matter When Thinking About Marijuana Policy: A Review of the Literature on the Elasticity of Demand." *Public Health Review*, 35(2): 1-18.

- Pacula RL**, Boustead A, and P Hunt (2014). "Words can be deceiving: A review of variation among legally effective medical marijuana laws in the United States." *Journal of Drug Policy Analysis*. ISSN (Online) 1941-2851, ISSN (Print) 2194-6337, DOI: [10.1515/jdpa-2014-0001](https://doi.org/10.1515/jdpa-2014-0001), May 2014
- Popovich I, French MT, **Pacula RL**, MacLean JC and OP Antonaccio (2014). "Cannabis Use and Antisocial Behavior among Youth." *Sociological Inquiry*, 84(1): 131-162.
- Galenianos M, **Pacula RL** and Persico N (2012). "A Search-Theoretic Model of the Retail Market for Illicit Drugs." *Review of Economic Studies*, 79, 1239-1269.
- Caulkins JP, Kilmer B, MacCoun R, **Pacula RL**, and Reuter PR (2012). "Design Considerations for Legalizing Marijuana." *Addiction*, 107(5): 865-871.
- Paddock S, Kilmer B, Caulkins JP, Booth M, and **RL Pacula** (2012) "An Epidemiological Model for Examining Marijuana Use over the Life Course." *Epidemiology Research International*, vol. 2012, Article ID 520894, 12 pages, 2012. doi:10.1155/2012/520894.
- Kilmer B, Caulkins JP, **Pacula RL**, and P Reuter (2011) "Bridging Perspectives to Illicit Markets: Estimating the Size of the U.S. Marijuana Market." *Drug and Alcohol Dependence*, 119(1-2): 153-160.
- Pacula RL** (2011). "Substance Use and Recessions: What can be learned from the alcohol literature?" *International Journal of Drug Policy*, 22(5): 326-334.
- Burgdorf J, Kilmer B and **RL Pacula** (2011). "Heterogeneity in the Composition of Marijuana Seized in California." *Drug and Alcohol Dependence*, 117(1): 59-61.
- Reuter PH, **Pacula RL**, and JC Caulkins (2011). "RAND's Drug Policy Research Center." *Addiction*, 106: 253-259.
- Nunberg H, Kilmer B, **Pacula RL**, and J Burgdorf (2011). "An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California." *Journal of Drug Policy Analysis*, 4(1). DOI: 10.2202/1941-2851.1017 Available at: <http://www.bepress.com/jdpa/vol14/iss1/art1>.
- Kilmer B, Eibner C, Ringel J and **RL Pacula** (2011). "Costs and savings associated with treating post-combat PTSD and depression: Insights from a microsimulation." *Psychological Trauma: Theory, Research, Practice, and Policy*, 3(2): 201-211.
- Pacula RL**, Kilmer B, Grossman M, and F Chaloupka (2010). "Risks and prices: The role of user sanctions in marijuana markets." *The B.E. Journal of Economic Analysis & Policy*, 10(1): (Contributions), Article 11.
- McCaffrey D, **Pacula RL**, Han B, and P Ellickson. (2010) "Marijuana Use and High School Drop Out: The Influence of Unobservables." *Health Economics*, 19: 1281-1299.
- MacCoun, R., **Pacula RL**, Chriqui JF, Harris K, and P Reuter (2009) "Do Citizens Know Whether Their State Has Decriminalized Marijuana? Assessing the Perceptual Component of Deterrence Theory." *Review of Law and Economics*, 5(11): 347-371.
- Pacula RL**, Ringel J, Dobkins C, and K Truong. (2008). "The Incremental Health Services Cost Associated with Marijuana Use." *Drug and Alcohol Dependence*, 92: 248-257.
- Eibner C, Morral A, **Pacula RL**, and J. MacDonald. (2006) "Is the Drug Court Model Exportable? An Examination of the Cost-Effectiveness of a Los Angeles-Based DUI Court." *Journal of Substance Abuse*

Treatment, 31(1): 75-85.

Ramchand R, **Pacula RL**, and M Iguchi. (2006). "Racial Differences in Marijuana-Users' Risk of Arrest in the United States." *Drug and Alcohol Dependence*, 84(3):264-72.

Caulkins JP and **RL Pacula** (2006). "Marijuana Markets: Inferences from Reports by the Household Population." *Journal of Drug Issues*, 36(1): 173-200.

Williams J, **Pacula RL**, Chaloupka FJ, and H Wechsler. (2006). "Cocaine Use in our Colleges." *Substance Use and Misuse*. 41(4): 489-509.

Williams J, **Pacula RL**, Chaloupka FJ, and H Wechsler. (2004). "Alcohol and Marijuana Use Among College Students: Economic Complements or Substitutes?" *Health Economics*, 13(9): 825-843.

Caulkins JP; **Pacula RL**; Paddock S, and J Chiesa. (2004). "What Can We – And Can't We – Expect from School-Based Drug Prevention?" *Drug and Alcohol Review*, 23(1): 79-87.

Pacula RL, Chriqui JF, Reichman DA, and Y Terry-McElrath (2002). "State Medical Marijuana Laws: Understanding the Laws and their Limitations." *Journal of Public Health Policy*, 23(4): 413-439.

Gitterman D, Sturm R, **Pacula RL**, and RM Scheffler (2001). "Does the Sunset of Mental Health Parity Really Matter?" *Administration & Policy in Mental Health*, 28(5): 353-369.

Kenkel D, Mathios AD, and **RL Pacula** (2001). "Economics of Youth Drug Use, Addiction and Gateway Effects." *Addiction* 96, Number 1, Special Issue: 151-164.

Czart C, **Pacula RL**, Chaloupka FJ, and H Wechsler (2001). "The Impact of Prices and Control Policies on Cigarette Smoking among College Students" *Contemporary Economic Policy*, 19(2): 135-149.

Sturm R and **RL Pacula** (2001). Private insurance: What has parity brought? *Behavioral Healthcare Tomorrow*, 10(2), SR26-28.

Pacula RL and FJ Chaloupka (2001). "The Effects of Macro-level Interventions on Addictive Behavior." *Substance Use and Misuse*, 36(13): 1901-1922.

Pacula RL and R Sturm (2000). "Mental Health Parity Legislation: Much Ado About Nothing?" *Health Services Research* 35(1 pt 2): 263-275.

Sturm R and **RL Pacula** (2000). "Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: I Limits." *Psychiatric Services*, 51(11): 1361.

Pacula RL and R Sturm (2000). "Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: II Copayments and Coinsurance." *Psychiatric Services* 51(12): 1487.

Sturm R., Gresenz C, **Pacula RL**, and K. Wells (1999). "Labor Force Participation by Persons with Mental Illness." *Psychiatric Services*, 51(11): 1407.

Sturm R and **RL Pacula** (1999). "State Mental Health Parity Laws: Cause or Consequence of Differences in Use?" *Health Affairs*, 18(5): 182-192.

Chaloupka FJ and **RL Pacula** (1999). "Sex and Race Differences in Young People's Responsiveness to Price and Tobacco Control Policies." *Tobacco Control*, 8: 373-377 (Winter)

Pacula RL (1998). "Does Increasing the Beer Tax Reduce Marijuana Consumption?" *Journal of Health Economics*, 17(5): 557-586.

Pacula RL (1997). "Women and Substance Use: Are Women More Susceptible to Addiction?" *American Economic Review*, 87(2): 454-459.

Pacula RL (1997). "Economic Modeling of the Gateway Effect." *Health Economics*, 6(5): 521-524.

Peer-Reviewed Books, Book Chapters, and Book Reviews

Powell D and **RL Pacula** (2017). "Prescription Opiates and Opioid Abuse: Regulatory Efforts to Limit Diversion from Medical Markets to Black Markets in the United States" in *Dual Markets - Comparative Approaches for Regulation*, edited by E. Savona and M.A.R. Kleiman. New York: Springer.

Maksabedian E, **Pacula RL**, Stein BD (2017). "Estimating the costs of substitution therapy for heroin and opioid addiction in the United States: Insights and challenges." In European Monitoring Centre for Drugs and Drug Addiction (2017), Drug treatment expenditure: a methodological overview, EMCDDA Insights 24, Publications Office of the European Union, Luxembourg. Doi: 10.2810/052028

Caulkins, J, Nicosia N and **RL Pacula**. (2014) "Economic Analysis and Policy Studies: Special Challenges in the Prevention Sciences" in *Defining Prevention Science*, edited by Z Sloboda and H Petras. New York: Springer. DOI 10.1007/978-1-489907424-2, chap25, Pgs 571- 596.

Caulkins JP and **RL Pacula** (2010) "Drug Policy Research" in P.G. Miller, J. Strang and P.M. Miller (eds), *Addiction Research Methods*, Wiley-Blackwell, Oxford UK doi: 10.1002/9781444318852 ch22.

Kilmer, B and **RL Pacula** (2010). "Drug Prevention and its Impact on Substance Use, Earnings and Educational Outcomes" in Levine P and D Zimmerman (Eds) *Targeting Investments in Children*, University of Chicago Press. Pgs. 181-220.

Pacula RL, Kilmer B and P Hunt (2010). "A framework for thinking about drug markets" in B Kilmer and S Hoorens (eds) *Understanding illicit drug markets, supply-reduction efforts, and drug-related crime in the European Union*. RAND Technical Report TR-755-EC. Cambridge, UK: RAND Europe, pp. 19-44.

Kilmer B, **Pacula RL**, Hunt P and L Rabinovich (2010). "Indicators for understanding supply-reduction efforts" in B Kilmer and S Hoorens (eds) *Understanding illicit drug markets, supply-reduction efforts, and drug-related crime in the European Union*. RAND Technical Report TR-755-EC. Cambridge, UK: RAND Europe, pp. 45-82.

Disley E, Hoorens S, Hunt P, Kilmer B, **Pacula RL**, Rabinovich L and J Rubin (2010). "Indicators for understanding drug-related crime" in B Kilmer and S Hoorens (eds) *Understanding illicit drug markets, supply-reduction efforts, and drug-related crime in the European Union*. RAND Technical Report TR-755-EC. Cambridge, UK: RAND Europe, pp. 83-104.

Burnam A and **RL Pacula**, (2009) "Insurance Parity" in G.L Fisher and N Roget (Eds) *Encyclopedia of Substance Abuse Prevention, Treatment, and Recovery*, Sage Publishing.

Eibner, C., Ringel, J.S.; Kilmer, B. **Pacula R.L.**; and C. Diaz. (2008). "The Cost of Post-Combat Mental Health and Cognitive Conditions." In Tanielian and Jaycox (Eds) *Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery*. RAND: Santa Monica.

Pacula, RL; MacCoun R; Reuter P.; Chiqui J.F.; Kilmer B.; Harris K; Paoli L; and C. Schaefer. (2005) “What does it mean to decriminalize cannabis? A cross-national empirical examination” in B. Lindgren and M. Grossman (Eds) Advances in Health Economics and Health Services Research Vol. 16: Substance Use: Individual Behavior, Social Interactions, Markets and Politics. Elsevier, Amsterdam pp.347-370

Hall, W. and **RL Pacula**. (2003). *Cannabis Use and Dependence: Public Health and Public Policy*. Melbourne, Australia: Cambridge University Press.

Pacula, RL; Grossman, M; Chaloupka, F.J.; P. O’Malley; L.D. Johnston and M.C. Farrelly. (2001) “Marijuana and Youth” (pp. 193-191). In Jonathan Gruber (Ed.), *Risky Behavior Among Youths: An Economic Analysis*. Chicago, IL: University of Chicago Press.

Chaloupka, F.J. and **RL Pacula**. (2001). "The Impact of Price on Youth Tobacco Use" (pp.193-199). In David M. Burns and Donald R. Shopland (Eds.), *Changing Adolescent Smoking Prevalence: Where Is It and Why? Smoking and Tobacco Control Monograph No. 14*. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub. No. 02-5086.

Chaloupka, F.J. and **RL Pacula**. (2000). “Economics and Anti-Health Behavior: The Economic Analysis of Substance Use and Abuse” (pp. 89-111). In W. Bickel and R. Vuchinich (Eds), *Reframing Health Behavior Change with Behavioral Economic*. Hillsdale, NJ: Lawrence Earlbaum Associates.

Peer-Reviewed Monographs, Reports and Congressional Testimony

Pacula RL (2017). Funding Considerations in the Fight Against the Opioid Epidemic: What the Science Tells Us. Testimony presented before the House Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies, April 5, 2017. RAND Congressional Testimony CT-469.

Pacula RL (2017). Regulating Medical Marijuana Markets: Insights from Scientific Evaluations of State Experiments. Testimony presented before the Florida House of Representatives Health & Human Services Committee, Subcommittee on Health Quality, Tallahassee Florida, January 25, 2017. RAND Congressional Testimony CT-461.

Pacula RL, Hunter SB, Ober AJ, Osilla KC, Vardavas R, Blanchard JC, Drabo EF, Leuschner KJ, Stewart W and J Walters. (2016). *Preventing, Identifying, and Treating Prescription-Drug Misuse Among Active-Duty Service Members*. RAND Report RR-1345-OSD. Santa Monica, CA March 2016.

Caulkins JC, Kilmer B, Kleiman MAR, MacCoun RJ, Midgette G, Oglesby P, **Pacula RL** and PH Reuter. (2015). *Considering Marijuana Legalization Insights for Vermont and Other Jurisdictions*, RAND Report RR-864. Santa Monica, CA, January 2015.

Kilmer B, Everingham S, Caulkins JP, Midgette G, Reuter P, **Pacula RL**, Burns R, Han B and R Lundberg. (2014). *What America’s Users Spend on Illicit Drugs: 2000-2010*. RAND Report RR-534-ONDCP. Santa Monica, CA, February 2014.

Kilmer B, Caulkins JP, Midgette G, Dahlkemper L, MacCoun RJ, and **RL Pacula**. (2013). Before the Grand Opening: Measuring Washington State’s Marijuana Market in the Last Year Before Legalized Commercial Sales” RAND Report, December 2013.

Pacula RL, Lundberg R, Caulkins JP, Kilmer B, Greathouse S, Fain T and P Steinberg (2013). *Improving the Measurement of Drug-Related Crime*. Office of National Drug Control Policy, February 2013.

- Ridgely, MS, **Pacula RL** and MA Burnam (2012). *Short Term Analysis to Support Mental Health Parity Implementation*. U.S. Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Disability, Aging and Long-Term Care Policy. February 2012. Available at: <http://aspe.hhs.gov/daltcp/reports/2012/mhsud.shtml>.
- Hoorens S, Hunt P, Malchiodi A, **Pacula RL**, Kadiyala S, Rabinovich L and B Irving (2012). *Measuring IPR infringements in the internal market: Development of a new approach to estimating the impact of infringements on sales*. RAND Technical Report TR-1279-EC . Cambridge, UK-RAND Europe.
- Kilmer B, JP Caulkins, **RL Pacula**, RJ MacCoun and PH Reuter (2010). *Altered State? Assessing How Marijuana Legalization in California Could Influence Marijuana Consumption and Public Budgets*. RAND Occasional Paper OP315. Santa Monica, CA: RAND
- Cave J, P Hunt, S Ismail, R Levitt, **RL Pacula**, L Rabinovich, J Rubin, K Weed and B Kilmer. (2010). *Tackling problem drug use*. RAND Technical Report TR-795-NAO. Cambridge, UK: RAND Europe.
- Pacula RL** (2010). “ An Assessment of the Scientific Support Underlying the FY2011 Budget Priorities of the Office of National Drug Control Policy” Testimony Presented before the House Oversight and Government Reform Committee, Subcommittee on Domestic Policy, Washington DC, April 14, 2010. RAND Congressional Testimony CT-344.
- Reuter PH, F Trautmann, **RL Pacula**, B Kilmer, A Gageldonk, D van der Gouwe (2009). *Assessing Changes in Global Drug Problems, 1998-2007: Main Report*. RAND Technical Report TR-704-EC. Cambridge, UK: RAND Europe.
- Kilmer B and **RL Pacula** (2009). *Estimating the size of the global drug market: A demand-side approach*. RAND Technical Report TR-711-EC. Cambridge, UK: RAND Europe.
- Pacula RL**, S. Hoorens, B Kilmer, PH Reuter, JR Burgdorf, and P Hunt (2009) “Issues in Estimating the Economic Cost of Drug Abuse in Consuming Nations” RAND Technical Report TR-709-EC. Cambridge UK: RAND Europe.
- Nicosia, N, **RL Pacula**, B Kilmer, R Lundberg, and J Chiesa (2009) *The Economic Cost of Methamphetamine Use in the United States, 2005*. RAND Research Monograph MG-829-MPF/NIDA. Santa Monica CA: RAND.
- Pacula RL** “The Economic Cost of Methamphetamine Use in the United States, 2005” Congressional Briefing held July 13, 2009, in Rayburn Building, Capitol Hill. Washington DC.
- Pacula RL** (2009) “Legalizing Marijuana: Issues to Consider Before Reforming California State Law” Testimony presented before the California State Assembly Public Safety Committee, Sacramento, CA October 28, 2009. RAND Congressional Testimony CT-334. Santa Monica, CA: RAND.
- Pacula RL** (2008). “What Research Tells Us About the Reasonableness of the Current Priorities of National Drug Control” Testimony presented before the House Oversight and Government Reform Committee, Subcommittee on Domestic Policy, Washington DC, March 12, 2008. RAND Congressional Testimony CT-302.
- Pacula, RL** and JP Caulkins, “How Well are Drug Prices Measured and Why do We Care?” Presentation to the National Academy of Sciences and Engineering, Committee on Law and Justice, October 12, 2007.

- Caulkins JC, **Pacula RL**, Arkes J, Reuter P, Paddock S, Iguchi M, and J Riley. (2004). *The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003*. Office of National Drug Control Policy. November.
- Arkes J, **Pacula RL**, Paddock S, Caulkins JC, and P Reuter. (2004). *Technical Report for the Price and Purity of Illicit Drugs Through 2003*. Office of National Drug Control Policy. November.
- Ringel J, Wasserman J, and **RL Pacula** (2003), *The Relationship Between Cigarette Use and Other Tobacco Products: Results from the 2000 National Youth Tobacco Survey*. Legacy First Look Report 10. Washington, DC: American Legacy Foundation.
- Caulkins J., **Pacula RL**, Paddock S and J. Chiesa (2002), *School-Based Drug Prevention: What kind of drug use does it prevent?* MR-1459-RWJ, RAND. Santa Monica, CA: RAND.
- Chriqui, JF; **Pacula, RL**; McBride, DC; Reichmann DA; VanderWaal CJ and Y Terry-McElrath (2002). *Illicit drug policies: Selected laws from the 50 states and the District of Columbia*, Berrien Springs, MI: Andrews University.
- Pacula, RL** Addictions: Entries and Exits. *Journal of Mental Health Policy and Economics*. 3(3): 165-166, 2000.
- Ringel J, **Pacula RL**, and J. Wasserman (2000), *The Relationship Between Cigarette Use and Other Tobacco Products: Results From the 1999 National Youth Tobacco Survey*, Legacy First Look Report 4. Washington, DC: American Legacy Foundation.
- Ringel, J, **Pacula RL**, and J. Wasserman (2000), *Youth Access to Cigarettes: Results from the 1999 National Youth Tobacco Survey*. Legacy First Look Report 10. Washington, DC: American Legacy Foundation.
- Working Papers, Presentations**
- About R, Powell D and **RL Pacula** (2017). “State Laws Improving Naloxone Access Reduce Overdose Risk”
- Midgett G, Vardavas R, Katkar P, Graf M, Smart R, Rutter C and **RL Pacula** (2017). “A Microsimulation Platform for Assessing the Impact of Policy on U.S. Alcohol Consumption and its Consequences.” Paper presented at Annual Meeting of the Research Society on Alcoholism, June 2017.
- Pacula RL**, Escarce J, Sorbero M et al. (2017). “Does Bigger Make You Better? Trends in provider performance measures across clinics within the same medical groups in Wisconsin.”
- Whaley C, **Pacula RL**, Ridgely MS, et al (2017). “State Differences in Trends in Physician-Hospital Integration: The hidden story behind national trends.”
- Weinberger G, **Pacula RL** and Hunt P (2017). “High on Crime? Exploring the Effects of Marijuana Dispensary Laws on Crime in California Counties”
- Stein BD, Burns R, Leslie D, **Pacula RL**, Dick A, Sorbero M, and AJ Gordon AJ (2016). “Trends and Disparities in Opioid Agonist Therapy Among Medicaid-Enrollees”
- Graf M, Midgett G and **RL Pacula** (2016). “Assessing the Effects of Alcohol Policies on Consumption: Why the Measurement of Consumption is Important.” Paper presented at annual meeting of Association for Public Policy Analysis and Management, November 2016.

- Pacula RL** and E Maksabedian (2016). “Mainstream Marijuana: Open Recreational Marijuana Dispensaries Increases Perceptions of Availability and Presence of Advertisements.”
- Saloga C, Weinberger G, Kilmer B and **RL Pacula** (2016). “Intoxication to go: Location and Density of Colorado's Licensed Off-Premise Marijuana and Alcohol Retail Outlets on June 1, 2016”
- Graf M, **Pacula RL**, Midgette G, Vardavas R and S Paddock (2016). “Assessing the Effects of Alcohol Policies on Consumption: Why the Measurement of Consumption Is Important” Paper presented at forthcoming Addiction Health Services Research Conference (Oct 2016) and APPAM meeting (Nov 2016).
- Pacula RL** “The Effects of Liberalizing Marijuana Policies on Use & Harms: Why Research Has Not Told us Much” Invited Presentation at the NIH Marijuana and Cannabinoids: A Neuroscience Research Summit (March 23, 2016)
- Pacula RL** “Heterogeneity of Marijuana Policies and What We are Learning that Really Matters for Use and Harms” Presentation given to the NIDA Cannabis Special Interest Group Speaker Series (September 18, 2014).
- Caulkins J, Kilmer B and **RL Pacula** (2012). “Marijuana Legalization: What We Know and What We Don’t” Congressional Briefing held July 17, 2012 in in Rayburn Building, Capitol Hill. Washington DC.
- Pacula RL**, Kadiyala S, Hunt P and A Malchiodi (2012). “An Alternative Framework for Empirically Measuring the Size of Counterfeit Markets” National Bureau of Economic Research Working Paper #18171, June 2012.
- Pacula RL** (2012). “Marijuana Legalization in the United States? State Initiatives and An Assessment of Impacts in California” Keynote address presented at SIRUS sponsored conference, “What do we know about Cannabis?” Oslo, Norway, May 2012.
- Pacula RL** (2011). “Substance Use and Recessions: Insights from economic analyses of alcohol and how drug use differs” Invited to give the “Alison Chesney and Eddie Killoran Memorial Lecture” at London School of Hygiene and Tropical Medicine, London UK, October 19, 2011.
- Pacula RL** “Why Existing Studies of the ‘War on Drugs’ Provide Little Guidance for Informing Policies Using a U.S.-Mexico perspective” Invited presentation at the Yale Center for the Study of Globalization’s Conference “Rethinking the ‘War on Drugs’ through the US-Mexico Prism” May 13, 2011.
- Pacula, RL** “Examining the Impact of Marijuana Legalization on Marijuana Consumption: Insights from the Economics Literature” RAND Working Paper Series WR-770-RC, July 2010.
- Pacula, RL** “Examining the Impact of Marijuana Legalization on Harms Associated with Marijuana Use” RAND Working Paper Series WR-769-RC, July 2010.
- Pacula, RL** “An Economic Perspective of Data and Analysis Needs for Public Stakeholders” Invited Presentation at the NIDA Clinical Trials Network (CTN) Cost-Effectiveness Evaluation in Addiction Treatment Trials Workshop, July 2009.
- Pacula, RL** “Why Economics Matters When Developing Drug Policy” Keynote Address given at the Workshop on the Economics of Alcohol, Tobacco and Illicit Drugs, Melbourne Australia, November 2005.

Papers Under Review

Taylor E, Malsberger R, Blanchard J, Mulcahy A, **Pacula RL** and D Powell. “Insurance Benefit Design Does Not Substantially Affect Opioid Use and Misuse for Disabled Medicare Beneficiaries” Under review at *Health Affairs* (January, 2018).

Alpert A, Powell D and **RL Pacula**. “A Transitioning Epidemic: How the Opioid Epidemic is Driving the Rise in Hepatitis C” Under review at *JAMA* (February, 2018).

Cantor J., Powell D, Kofner A, **Pacula RL** and BD Stein. “21st Century Cures Act State Funding Varies by Opioid-Related Mortality Rates and State Population” Under review at *American Journal of Public Health* (December, 2017).

Azofeifa A, Schauer G, Mattson ME, and **RL Pacula**. “Assessing Cannabis Growers in the United States.” Under review at *International Journal of Drug Policy* (December, 2017).

Powell D, **Pacula RL**, and E Taylor. “Did Medicare Part D Contribute to the Rise in Opioid Overdose Deaths in the US?” Under review at *American Economic Journal: Applied* (November, 2017). Also available as an National Bureau of Economic Research Working Paper #21072.

THESIS ADVISING

Ervant Maksabedian, Ph.D. 2017. Pardee RAND Graduate School (Committee Chair) “The effects of MHPAEA on Access to Medication-Assisted Treatments for Opioid Use Disorders.”

Julie Johnson, Ph.D. 2015. Heller School of Social Policy and Management, Brandies University (Committee Member) “Do Liberalized Marijuana Policies Affect Adolescent Tobacco, Alcohol, Marijuana and Other Drug Use?: A State-Level Analysis.”

James Burgdorf, Ph.D. 2013. Pardee RAND Graduate School (Committee Chair) “Health Insurance and Poor Health: Bleeding the Stock of Self-Employed Workers?”

Jennifer Wong, Ph.D. 2009. Pardee RAND Graduate School (Committee Member) “No Bullies Allowed: Understanding Peer Victimization, the Impacts on Delinquency, and the Effectiveness of Prevention Programs.”

Khoa D Truong, Ph.D. 2008. Pardee RAND Graduate School (Committee Member). “Essays on Environmental Determinants of Health Behaviors and Outcomes.”

Beau Kilmer, Ph.D. 2007. Kennedy School of Government, Harvard University (Committee Member). “Essays on the Consequences of Drug Use and Drug Testing.”

OTHER PROFESSIONAL ACTIVITIES

Vice President, *International Society for the Study of Drug Policy* (ISSDP), 2015-2019.

Member, National Institute on Drug Abuse Marijuana Policy Research Workgroup, 2017.

Assistant Editor, *Addiction*, December 2005 - present.

Associate Editor, *Journal of Drug Policy Analysis*, Fall 2010 – present.

Editorial Board, *International Journal of Drug Policy*, Fall 2011 – present.

Elected Member of Coordinating Committee, International Society for the Study of Drug Policy (ISSDP), 2011-2015.

Member, Monitoring the Future National Advisory Committee, March 2014 – present.

Program Chair, Tobacco, Alcohol and Other Drugs, *American Society for Health Economics* Biennial Conference, Philadelphia PA, June 2016.

Program Chair, *International Society for the Study of Drug Policy* 2016 Regional Meeting, New York City, NY, April 2016

Consultant, Robert Wood Johnson Foundation funded, LawAtlas Medical Marijuana Dataset, July 2013 – present.

Faculty Mentor, Titus Galama's K Award from the National Institute on Aging, March 2013 – present.

American Society for Health Economics (ASHE) 2014 Host Committee Member, Fifth Biennial Conference, 2013-2014.

Conference organizer, RAND BING Conference on Health, Aging and Human Capital to be held in Santa Monica, CA December 2-3, 2011.

American Society for Health Economics (ASHE) Awards Committee, December 2009 – 2013.

Member of the APPAM Conference Program Committee, Fall 2008 and Fall 2009.

Conference Host and Program Chair for 4th Annual Meeting of the *International Society for the Study of Drug Policy* (ISSDP), to be held at RAND Santa Monica, CA., March 2010.

One of 13 members appointed to the Health Services Research Subcommittee, *National Institute on Drug Abuse* Initial Review Group-F, June 2003 – June 2007.

Conference Planner for 2005 *Addiction Health Services Research Meeting* co-hosted by UCLA and RAND, Santa Monica, CA, October 2005.

One of 11 people appointed to review the 2003 National Research Council and Institute of Medicine's report *Reducing Underage Drinking: A Collective Responsibility*, Committee on Developing a Strategy to Reduce and Prevent Underage Drinking, Richard J. Bonnie and Mary Ellen O'Connell Editors.

One of 12 members appointed to the Health Services Research Review Subcommittee of the *National Institute on Alcohol Abuse and Alcoholism* Initial Review Group, (AA-2), July 2001-October 2002.

Regular reviewer for the following journals and foundations: *Addiction*, *American Economic Review*, *Contemporary Economic Policy*, *Health Affairs*, *Health Economics*, *Health Services Research*, *Journal of Health Economics*, *Journal of Policy Analysis and Management*, *Journal of Political Economy*, *Journal of Research in Crime and Delinquency*, *Law and Economics*, *Review of Economics and Statistics*, *Review of Law and Economics*, *Forum for Health Economics & Policy*, *Medical Care*, *National Science Foundation*, *Robert Wood Johnson Foundation* and *Tobacco Control*.

FUNDED RESEARCH

Co-Principal Investigator on a grant from the National Institute on Drug Abuse entitled “Prescription Drug Coverage, Access to Opioids and Drug Abuse” September 2017 through August 2019.

Investigator on a contract from the Pew Charitable Trust to study “Opioid State Policies, Use Disorders, and Treatment” September 2017 through May 2018.

Investigator on a U19 Center grant from the Agency for Healthcare Research and Quality entitled “Understanding Health Care Delivery Systems PCOR Adoption and System Performance” September 2015 through August 2020.

Principal Investigator on a grant from the National Institute on Drug Abuse entitled “RAND Alcohol Policy Platform” December 2016 through April 2019.

Investigator on a contract from the Office of National Drug Control Policy entitled “What American Users Spend on Illicit Drugs” August 2017 through July 2018.

Investigator on a grant from the National Institute on Drug Abuse entitled “The Impact of Benefit Design and Formulary Practices on Opioid Abuse and Overdose” September 2014 through September 2016.

Principal Investigator on a grant from the National Institute on Drug Abuse entitled “International Alcohol Policy Model” May 2014 through November 2016.

Principal Investigator on a contract from the Department of Defense entitled “Preventing and Managing Prescription Drug Misuse Among Military Personnel” May 2012 through July 2015.

Investigator on a grant from the National Institute on Drug Abuse entitled “Opioid Agonist Treatment (OAT) Expansion in Medicaid – The Role of Buprenorphine” August 2012 through July 2016.

Principal Investigator on a grant from the National Institute on Drug Abuse entitled “Implementation of Medical Marijuana and its Impact on Health” September 2011 through August 2016.

Principal Investigator on Administrative Supplement from the National Institute on Drug Abuse entitled “Research on Marijuana Legalization in the US (Admin Suppl)” September 2013 through August 2014.

Co-Investigator (PI on subcontract to RAND) on a grant from the National Institute on Drug Abuse entitled “Parity and Addiction Act: Impact on Benefits, Use and Costs” September 2011 through September 2014.

Principal Investigator on a contract with the Office of National Drug Control Policy entitled “Measuring Drug Related Crime” July 2011 through September 2012.

Co-Director on a contract with the U.S. Department of Health and Human Services entitled “Short Term Analysis to Support Mental Health Parity Implementation”, September 2010 through August 2011.

Co-Investigator on a contract with the European Commission entitled “Drug Supply Reduction and Drug-Related Crime”, September 2008 through June 2009.

Co-Principal Investigator on a grant from the National Institute on Drug Abuse entitled “Evaluating the Role of Race in Criminal Justice Referrals to Treatment”, March 2008 through February 2012.

Co-Investigator on a contract with the European Commission entitled “Global Markets for Drugs” January 1, 2008 through December 31, 2008.

Principal Investigator on a contract with the Meth Project Foundation entitled "Economic Cost of Methamphetamine Use in 2005" December 1, 2007 through November 30, 2008.

Principal Investigator on a grant from the National Institute on Drug Abuse entitled "The Economic Cost of Drug Use?" May 10, 2006 through April 30, 2011.

Principal Investigator on a grant from the National Institute of Drug Abuse entitled "Are There Economic Costs to Marijuana Use?" February 05, 2000 through January 31, 2004. Received continuing renewal grant for August 2004 through July 2007.

Principal Investigator on a grant from the Robert Wood Johnson foundation entitled "Exploring the Relationship Between Marijuana Policy and Price" January 2004 through December 2005.

Co-Investigator on a grant from the Robert Wood Johnson Foundation entitled "Understanding The Impact Of Funding Volatility On Treatment Services" September 2004 through August 2006.

Principal Investigator on a grant from the Robert Wood Johnson Foundation entitled "Within- and Cross-National Analyses of the Effects of Cannabis Depenalization" July 01, 2002 through June 30, 2005.

Principal Investigator on a government task order from the Office of National Drug Control Policy entitled "The Price of Illicit Drugs" September 2002 through May 2004.

Co-Principal Investigator on a grant from the Robert Wood Johnson Foundation entitled, "State Illicit Drug Surveillance System." Duane McBride, Principal Investigator. January 1, 2000 through February 2004.

Co-Investigator on a grant from the National Institute of Drug Abuse entitled "Consequences of Drug Use." Phyllis Ellickson, Principal Investigator. July 2000 through November 2003.

Principal Investigator on a grant from the Robert Wood Johnson Foundation entitled "Are there Unintended Consequences of Alcohol and Tobacco Policies on College Campuses?" Frank Chaloupka, Co-Investigator. November 1, 1998 through October 31, 2001.

Co-Investigator on a grant from the Robert Wood Johnson Foundation entitled "Estimating the Effects of Drug Prevention Programs on the Use of Cocaine, Marijuana, Cigarettes and Alcohol." Jonathan Caulkins, Principal Investigator. March 3, 2000 through June 30, 2001.

Co-Investigator on a grant from the Robert Wood Johnson Foundation entitled "The Impact of Environmental Factors on Youth and Young Adult Tobacco Use," Frank Chaloupka Principal Investigator, Michael Grossman and Henry Saffer Co-Principal Investigators. October 1, 1997 through September 30, 1999.

Co-Investigator on a grant from the Center for Disease Control and Prevention entitled "Price, Availability, and Youth Tobacco Use" Frank Chaloupka Principal Investigator. September 1, 1997 through September 30, 1998.

Research Specialist on a grant from the Robert Wood Johnson Foundation entitled "Youth Alcohol, Tobacco and Other Drug Surveillance Initiative," Frank Chaloupka, Project Director. November 1, 1997 through October 31, 1999.

Research Specialist on a grant from the Robert Wood Johnson Foundation entitled "Youth Alcohol, Tobacco, and Other Drug Surveillance Initiative: Planning Proposal," Frank Chaloupka, Project Director. October 1, 1997 through October 31, 1997.

Principal Investigator on a grant from the National Institute on Alcohol Abuse and Alcoholism entitled “The Development of Demand for Intoxicating Substances.” August 1, 1993 through July 31, 1995.

HONORS AND AWARDS

- 2017 Keynote Speaker at the Lisbon Addictions Conference, October 26, 2017, Lisbon, Portugal.
- 2017 Keynote Speaker at the 11th Annual International Society for the Study of Drug Policy (ISSDP) Scientific Meeting, May 18 Aarhus, Denmark.
- 2016 UK Prospect Magazine Think Tank Best Paper Award in the area of US Social Policy for paper with B Stein, et al (2016) “Underutilized physician capacity to treat opioid use disorder with buprenorphine opioid agonist medication assisted treatment.” JAMA, 316(11): 1211-1212.
- 2015 Stanley Reiter Best Paper Award for paper with M Galenianos and N Persico (2012) “A Search-Theoretical Model of the Retail Market for Illicit Drugs.” Review of Economic Studies. 79(2): 1239-1269.
- 2014 first speaker to kick off NIDA- sponsored Cannabis Special Interest Group Speaker Series, September 18, Rockville, Maryland.
- 2013 invited expert to first ever ONDCP Conference on Drug Policy Reform, December 9, 2013, The White House, Washington DC.
- 2013 invited Seminar Speaker at Columbia University’s “Grand Rounds”, September 29, New York City.
- 2012 invited Seminar Speaker at organized “The Price of Alcohol and Related Harms” Meeting with UK Policy Makers, February 23, London .
- 2012, invited Keynote Speaker at SIRUS sponsored conference, “What do we know about Cannabis?” Oslo, Norway, May 16.
- 2011 invited to give “The Alison Chesney & Eddie Killoran Memorial Lecture” London School of Hygiene and Tropical Medicine, London UK
- 2010 recipient of RAND President’s Award, recognizing individuals exemplifying RAND’s core values of quality and objectivity and who have made exemplary contributions to the RAND community
- Selected to be the Keynote Speaker at the 2008 Australian Professional Society on Alcohol and Other Drugs (Sydney, November 2008)
- Featured in a research summary the *NBER Reporter* publication (Winter 2005).
- 2004 Winner of RAND Bronze Merit Award for contributions to RAND’s Mission Statement through expansion of research, July 2004.
- Participant in first “Creating Career Opportunities For Female Economists” Conference sponsored by CWEP and the National Science Foundation, January 5-7, 1998.
- University of San Diego School of Business *Top Teachers* List, Fall, 1995
- Magna Cum Laude, 1990.
- Phi Beta Kappa, 1990.
- Alpha Sigma Nu, 1990.